Nadine Tung, MD on A Phase II Study of Olaparib Monotherapy in Breast Cancer #ASCO2020 #ASCO @DanaFarber @Harvard

Nadine Tung, MD on A Phase II Study of Olaparib Monotherapy in Breast Cancer #ASCO2020 #ASCO @DanaFarber @Harvard

User Photo
Cancer-News

4 months
29 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Nadine Tung, MD of Dana Farber/Harvard Cancer Center @DanaFarber @Harvard discusses a phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes presented at this year's virtual ASCO.
Up Next Autoplay
>